Media and Communications



Friday, September 12, 2014
Teva Presents New Clinical Safety Data in RRMS Patients Treated with Laquinimod for Two or More Years at Joint ACTRIMS-ECTRIMS Meeting

JERUSALEM & LUND, Sweden--(BUSINESS WIRE)--Sep. 12, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Active Biotech (NASDAQ OMX NORDIC:ACTI) today announced new follow-up data evaluating the clinical safety of laquinimod in patients with relapsing-remitting multiple sclerosis (RRMS) who were treated with laquinimod in Phase II, Phase III and open-label extension studies for two or more years. The pooled safety analysis of the Phase II LAQ/5063 and the Phase III ALLEGRO and BRAVO extension studies supports findings observed in t Read More »

Friday, September 12, 2014
Teva Presents Gene Expression Analysis at Joint Actrims-Ectrims Meeting Demonstrating Copaxone® (Glatiramer Acetate Injection) Has a Complex Profile

Data Explore Differences between Gene Expression Profiles of Teva’s COPAXONE® and Other Glatiramer Acetate Products JERUSALEM--(BUSINESS WIRE)--Sep. 12, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that new scientific data presented at the MS Boston 2014: Joint ACTRIMS-ECTRIMS Meeting reveals differences in the gene expression profile between COPAXONE® (glatiramer acetate injection) and other glatiramer acetate products. In this research, a human monocyte cell line was stimulated by either Read More »

Thursday, September 11, 2014
Teva Presents New Data Which Demonstrate Reduction of Injection-Related Adverse Events with the Less Frequent Dosing of Three-times-a-week COPAXONE® (glatiramer acetate injection) 40 mg Compared to Daily COPAXONE® 20 mg

JERUSALEM--(BUSINESS WIRE)--Sep. 11, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced new data from the open-label Phase IIIb GLatiramer Acetate low frequenCy safety and patIent ExpeRience (GLACIER) study, comparing the safety and tolerability of three-times-a-week COPAXONE® (glatiramer acetate injection) 40 mg to daily COPAXONE® 20 mg in patients with relapsing-remitting multiple sclerosis (RRMS). During a platform presentation this week, the results from the GLACIER study were shared at the MS Boston 201 Read More »

Thursday, August 07, 2014
Teva Comments on Receipt of First Paragraph IV Notice for COPAXONE® 40 mg/mL (glatiramer acetate injection) Formulation

JERUSALEM--(BUSINESS WIRE)--Aug. 7, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today confirmed that it has received the first paragraph IV notice for its three-times-a-week COPAXONE® 40 mg/mL product from Dr. Reddy’s Laboratories, Inc. Teva will continue to vigorously defend its COPAXONE® intellectual property rights against infringement wherever they are challenged. Teva intends to file a lawsuit for patent infringement against Dr. Reddy’s within the 45 day period provided under the Hatch-Waxman Act. The filing of the law Read More »

Friday, July 04, 2014
Teva Receives CHMP Positive Opinion for Seasonique® Extended-Regimen Contraceptive for Marketing Authorization in Several European Countries

An Extended Regimen Oral Contraceptive That Provides Quarterly Menses – A New Concept for Women in Europe JERUSALEM--(BUSINESS WIRE)--Jul. 4, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion in a referral procedure regarding the authorization of its extended-regimen oral contraceptive, Seasonique® (levonorgestrel (0.15 mg)/ethinyl estradiol (0.03 mg) and low-dose ethinyl e Read More »

Friday, June 20, 2014
Teva Reaches Settlement in ProAir® HFA Patent Case

JERUSALEM--(BUSINESS WIRE)--Jun. 20, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced that it has reached a settlement with Perrigo Pharmaceutical Co. and Catalent Pharma Solutions LLC with respect to four patents for Teva’s ProAir® HFA (albuterol sulfate) Inhalation Aerosol product. This settlement provides a license to Perrigo and Catalent to sell limited units of Perrigo’s generic version of the product for an initial period beginning Dec. 19, 2016 and lasting until June 2018, when the limits will no longer apply. Read More »

Thursday, June 12, 2014
Teva Announces U.S. Court of Appeals Upholds Ruling Confirming Invalidity of Baraclude® Patent

JERUSALEM--(BUSINESS WIRE)--Jun. 12, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that the U.S. Court of Appeals for the Federal Circuit today upheld a ruling by the U.S. District Court for the District of Delaware finding Bristol-Myers Squibb’s entecavir compound claim of U.S. Patent No. 5,206,244 invalid. Teva’s ANDA for entecavir has received tentative approval from the U.S. Food and Drug Administration (FDA). Teva will finalize the launch plans for this product once it receives final approval from the FDA. Read More »

Tuesday, June 03, 2014
Teva to Acquire Labrys Biologics, Inc.: Novel Migraine Prophylaxis Treatment Adds Significant New Dimension to Teva’s Growing Pain Care Franchise

Adds LBR-101, Labrys’ Phase IIb anti-CGRP monoclonal antibody for the prevention of chronic and high frequency episodic migraine. Peak sales potential of $2-3 billion. Teva ideally positioned in the transformational pain market with a wide range of new chemical and biologic entities and NTEs to treat a broad spectrum of pain disorders JERUSALEM & SAN MATEO, Calif.--(BUSINESS WIRE)--Jun. 3, 2014-- Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) and Labrys Biologics, Inc., a priva Read More »

Friday, May 30, 2014
Teva Receives Favorable Court Decision Regarding Generic Celebrex® Capsules; Teva Should Receive Sole Exclusivity for Generic Celebrex® Capsules

JERUSALEM--(BUSINESS WIRE)--May 30, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that the U.S. District Court for the Northern District of West Virginia denied a motion filed by Mylan and issued an opinion and order affirming a decision by the FDA under which Teva should receive sole 180-day “first-to-file” exclusivity for generic Celebrex® (celecoxib) 100, 200 and 400 mg capsules. On April 17th,Teva entered into a settlement agreement with Pfizer related to Teva’s generic version of Celebrex® (celecoxib) 5 Read More »

Wednesday, April 30, 2014
Teva Reports Positive Results from Pivotal Phase III Study to Evaluate Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Moderate to Severe Chronic Low Back Pain

Data provides promise for a twice-daily, acetaminophen-free hydrocodone designed with potential abuse-deterrent properties JERUSALEM--(BUSINESS WIRE)--Apr. 30, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced positive results from a pivotal Phase III study of hydrocodone bitartrate extended-release tablets designed with Teva’s proprietary technology providing potential abuse-deterrent properties (CEP-33237). The results showed significant improvement in the treatment of patients’ chronic low back pain as Read More »